文献速递小儿神经外科与脑积水神经重症

重新评估脑室胸膜分流术:现代条件下的长期有效性与并发症发生率

Reevaluation of Ventriculopleural Shunting: Long-Term Efficacy and Complication Rates in the Modern Era.
PubMed 文献 · World Neurosurg · 2020-03-16

该单中心回顾性分析纳入35例连续接受脑室胸膜分流术(VPLS)的患者,平均随访64.1个月,累积总体分流存活率1年70%、3年44%、5年28%;有症状性胸腔积液累积发生率1年18%、2年23%、3年46%。作者认为随着分流技术现代化VPLS存活率似乎有所改善,VPLS是脑室腹腔分流术(VPS)不可行时合理的二线选择。

要点

  • VPLS累积总体分流存活率1年70%、3年44%、5年28%,平均随访64.1个月。
  • 排除3例(8.6%)因过度引流行单纯阀门更换并保留VPLS者后,存活率1年76%、3年51%、5年34%,中位分流存活时间3.0年。
  • 有症状性胸腔积液累积发生率1年18%、2年23%、3年46%,中位发生时间1.1年。

核心结论

  • 作者认为随着更现代的分流技术,VPLS存活率似乎有所改善。
  • 作者认为VPLS是VPS不可行时合理的二线选择。
  • 作者指出胸腔积液的可能性不可忽视,但无症状或轻度积液可保守处理。

研究设计与样本

  • 单中心回顾性分析纳入35例连续接受VPLS的患者,计算分流存活率与有症状性胸腔积液发生率并评估危险因素。

主要发现

  • VPLS后平均随访64.1个月,累积总体分流存活率1年70%、3年44%、5年28%。
  • 分流失败患者中3例(8.6%)因过度引流行单纯阀门更换(固定压阀门改为可调压阀门)并保留VPLS。
  • 排除上述3例后,分流存活率1年76%、3年51%、5年34%,中位分流存活时间3.0年。
  • 未发现与分流存活显著相关的因素。
  • 有症状性胸腔积液累积发生率1年18%、2年23%、3年46%,从VPLS置入到出现有症状性胸腔积液的中位时间1.1年。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ventriculopleural shunting (VPLS) is recognized as an alternative method when the standard ventriculoperitoneal shunting (VPS) is not applicable. Nevertheless, there is limited clinical evidence of its effectiveness including long-term patency. METHODS: Data on 35 consecutive patients who underwent VPLS at a single institution were retrospectively analyzed. The rates of shunt survival and incidence of symptomatic pleural effusion were calculated, and risk factors were evaluated. RESULTS: Mean follow-up after VPLS was 64.1 months. The cumulative overall shunt survival rates were 70%, 44%, and 28% at 1, 3, and 5 years, respectively. Among patients with shunt failure, 3 (8.6%) with overdrainage underwent simple valve replacement (from fixed to programmable valve) and retained a VPLS. If these patients are excluded, shunt survival rates were 76%, 51%, and 34% at 1, 3, and 5 years, respectively, and the median shunt survival time was 3.0 years. No factor was significantly associated with shunt survival. Cumulative rates of symptomatic pleural effusion were 18%, 23%, and 46% at 1, 2, and 3 years, respectively. Median time from VPLS placement to symptomatic pleural effusion was 1.1 years. CONCLUSIONS: It seems that VPLS survival has improved with more modern shunt technology. VPLS is a reasonable second-line option when VPS is not feasible. The possibility of pleural effusion is not negligible, but asymptomatic/mild effusions may be managed conservatively.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Hasegawa H, Rinaldo L, Meyer FB, et al. Reevaluation of Ventriculopleural Shunting: Long-Term Efficacy and Complication Rates in the Modern Era. World Neurosurg. 2020. PMID: 32194273. doi:10.1016/j.wneu.2020.03.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。